线状IgA大疱性皮病的研究进展

doi:10.35541/cjd.20200496

中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (10): 925-928.doi: 10.35541/cjd.20200496

线状IgA大疱性皮病的研究进展

荆可,李锁,冯素英

中国医学科学院、北京协和医学院皮肤病医院皮肤科，南京 210042

收稿日期:2020-05-21 修回日期:2021-07-15 发布日期:2022-10-08
通讯作者: 冯素英 E-mail:fengsy@pumcderm.cams.cn
基金资助:
中国医学科学院医学与健康科技创新工程（CIFMS-2017-I2M-1-017）

Linear IgA bullous dermatosis

Jing Ke, Li Suo, Feng Suying

Department of Dermatology, Hospital of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China

Received:2020-05-21 Revised:2021-07-15 Published:2022-10-08
Contact: Feng Suying E-mail:fengsy@pumcderm.cams.cn
Supported by:
CAMS Innovation Fund for Medical Sciences（CIFMS-2017-I2M-1-017）

摘要/Abstract

摘要： 【摘要】线状IgA大疱性皮病（LABD）是一种少见的自身免疫性表皮下水疱病。目前针对LABD的研究尚不完善，多为病例报道。本文综述LABD的病因和发病机制、临床及组织病理表现、诊断及治疗等方面的近期研究。

关键词: 皮肤疾病, 水疱大疱性, 线状IgA大疱性皮病, 治疗

Abstract: 【Abstract】 Linear IgA bullous dermatosis （LABD） is a rare autoimmune subepidermal blistering disease. Currently, researches on LABD are still limited, and most are case reports. This review summarizes research advance in etiology and pathogenesis, clinical and histopathological manifestations, diagnosis and treatment of LABD.

Key words: Skin diseases, vesiculobullous, Linear IgA bullous dermatosis, Treatment

荆可李锁冯素英. 线状IgA大疱性皮病的研究进展[J]. 中华皮肤科杂志, 2022,55(10):925-928. doi:10.35541/cjd.20200496

Jing Ke, Li Suo, Feng Suying. Linear IgA bullous dermatosis[J]. Chinese Journal of Dermatology, 2022, 55(10): 925-928.doi:10.35541/cjd.20200496

参考文献 33

［1］	Lammer J, Hein R, Roenneberg S, et al. Drug⁃induced linear IgA bullous dermatosis: a case report and review of the literature［J］. Acta Derm Venereol, 2019,99（6）:508⁃515. doi: 10.2340/00015 555⁃3154.
［2］	Fortuna G, Marinkovich MP. Linear immunoglobulin A bullous dermatosis［J］. Clin Dermatol, 2012,30（1）:38⁃50. doi: 10.1016/j.clindermatol.2011.03.008.
［3］	Tsuchisaka A, Ohara K, Ishii N, et al. Type VII collagen is the major autoantigen for sublamina densa⁃type linear IgA bullous dermatosis［J］. J Invest Dermatol, 2015,135（2）:626⁃629. doi: 10.1038/jid.2014.381.
［4］	Cozzani E, Di Zenzo G, Gasparini G, et al. Autoantibody profile of a cohort of 54 Italian patients with linear IgA bullous dermatosis: LAD⁃1 denoted as a major auto⁃antigen of the lamina lucida subtype［J］. Acta Derm Venereol, 2020,100（4）:adv00070. doi: 10.2340/00015555⁃3415.
［5］	Edwards G, Diercks G, Seelen M, et al. Complement activation in autoimmune bullous dermatoses: a comprehensive review［J］. Front Immunol, 2019,10:1477. doi: 10.3389/fimmu.2019.01477.
［6］	Hoffmann J, Hadaschik E, Enk A, et al. Linear IgA bullous dermatosis secondary to infliximab therapy in a patient with ulcerative colitis［J］. Dermatology, 2015,231（2）:112⁃115. doi: 10.1159/000431172.
［7］	Riemenschneider K, Diiorio DA, Zic JA, et al. Drug⁃induced linear IgA bullous dermatosis in a patient with a vancomycin⁃impregnated cement spacer［J］. Cutis, 2018,101（4）:293⁃296.
［8］	Tadiotto Cicogna G, Ferranti M, Vaccari D, et al. Topical imiquimod⁃induced linear IgA bullous dermatosis［J］. BMJ Case Rep, 2019,12（7）:e230037. doi: 10.1136/bcr⁃2019⁃230037.
［9］	Tiger JB, Rush JT, Barton DT, et al. Urticarial linear IgA bullous dermatosis （LABD） as a presenting sign of chronic lymphocytic leukemia （CLL）［J］. JAAD Case Rep, 2015,1（6）:412⁃414. doi: 10.1016/j.jdcr.2015.10.001.
［10］	Colmant C, Camboni A, Dekeuleneer V, et al. Linear IgA dermatosis in association with angioimmunoblastic T⁃cell lymphoma infiltrating the skin: a case report with literature review［J］. J Cutan Pathol, 2020,47（3）:251⁃256. doi: 10.1111/cup.13576.
［11］	Kanda N, Nakadaira N, Otsuka Y, et al. Linear IgA bullous dermatosis associated with ulcerative colitis: a case report and literature review［J］. Australas J Dermatol, 2020,61（1）:e82⁃e86. doi: 10.1111/ajd.13121.
［12］	Malipatel R, Gnanapriya V, Manocha A, et al. Systemic lupus erythematosus with linear IgA bullous dermatosis and renal vascular lesions: an extremely rare association［J］. Indian J Nephrol, 2018,28（6）:465⁃467. doi: 10.4103/ijn.IJN_200_17.
［13］	Tieppo Francio V, Towery C, Davani S, et al. Previously misdiagnosed linear IgA dermatosis resolved with dapsone［J］. BMJ Case Rep, 2018,2018:bcr2017220623. doi: 10.1136/bcr⁃2017⁃220623.
［14］	Ikkaku N, Tateishi C, Oda Y, et al. Linear immunoglobulin A bullous dermatosis developing during late pregnancy［J］. J Dermatol, 2017,44（3）:e44⁃e45. doi: 10.1111/1346⁃8138.13475.
［15］	陈吉辉, 苟辉, 张敏, 等. 妊娠期并发成人型线状IgA大疱性皮病1例报告［J］. 四川大学学报（医学版）, 2019,50（2）:288.
［16］	Shetty VM, Pai SB, Rao R. Linear IgA bullous dermatosis presenting as chronic prurigo: unveiling of the diagnosis by serrated pattern analysis［J］. Int J Dermatol, 2018,57（11）:e147⁃e149. doi: 10.1111/ijd.14253.
［17］	Vives Ricoma E, El Uali Abeida M, Viso Soriano MJ, et al. Linear IgA bullous dermatosis with laryngeal involvement［J］. Acta Otorrinolaringol Esp, 2020,71（3）:190⁃192. doi: 10.1016/j.otorri.2019.05.006.
［18］	Shah S, Mohr B, Parekh P. Linear IgA bullous dermatosis mimicking oral lichen planus［J］. Proc （Bayl Univ Med Cent）, 2017,30（3）:360⁃361. doi: 10.1080/08998280.2017.11929649.
［19］	Wang H, Wang X, Yang B, et al. Image gallery: onychomadesis in linear IgA bullous dermatosis［J］. Br J Dermatol, 2020,182（5）:e160. doi: 10.1111/bjd.18744.
［20］	Choudhry SZ, Kashat M, Lim HW. Vancomycin⁃induced linear IgA bullous dermatosis demonstrating the isomorphic phenomenon［J］. Int J Dermatol, 2015,54（11）:1211⁃1213. doi: 10.1111/ijd.12944.
［21］	Mesa⁃Álvarez L, Peón Currás G, Flórez Á. Widespread erythematous and bullous plaques associated with nasolabial fold ulceration: answer［J］. Am J Dermatopathol, 2019,41（3）:237⁃238. doi: 10.1097/DAD.0000000000001051.
［22］	Nguyen JK, Koshelev MV, Gill BJ, et al. A toxic epidermal necrolysis⁃like presentation of linear IgA bullous dermatosis treated with dapsone［J］. Dermatol Online J, 2017,23（8）:13030/qt4443157h.
［23］	Helmandollar KJ, Hoverson KR, Falkner RC, et al. Diffuse vesiculobullous eruption with systemic findings［J］. Dermatol Online J, 2018,24（5）:13030/qt09m1x0c1.
［24］	Fulton E, Jan F, Zimarowski MJ. Flame figures in linear IgA bullous dermatosis: a novel histopathologic finding［J］. Dermatol Online J, 2017,23（11）:13030/qt1qs7m39f.
［25］	Díaz MS, Morita L, Ferrari B, et al. Linear IgA bullous dermatosis: a series of 17 cases［J］. Actas Dermosifiliogr, 2019,110（8）:673⁃680. doi: 10.1016/j.ad.2018.06.017.
［26］	Ohata C, Ishii N, Koga H, et al. A clinical and serological study of linear IgA bullous dermatosis without linear immunoglobulin deposition other than IgA at the basement membrane zone using direct immunofluorescence［J］. Br J Dermatol, 2017,177（1）:152⁃157. doi: 10.1111/bjd.15232.
［27］	Shan XF, Zhang FR, Tian HQ, et al. A case of linear IgA dermatosis successfully treated with tetracycline and niacinamide［J］. Int J Dermatol, 2016,55（4）:e216⁃e217. doi: 10.1111/ijd. 12524.
［28］	Cui YX, Yang BQ, Zhou GZ, et al. Childhood linear IgA bullous dermatosis successfully treated with oral nicotinamide［J］. Clin Exp Dermatol, 2016,41（7）:816⁃818. doi: 10.1111/ced.12892.
［29］	Kaya İslamoğlu ZG, Akyürek FT. A case of recalcitrant linear IgA bullous dermatosis: successfully treated with rituximab［J］. Dermatol Ther, 2019,32（3）:e12911. doi: 10.1111/dth.12911.
［30］	Lamberts A, Euverman HI, Terra JB, et al. Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases［J］. Front Immunol, 2018,9:248. doi: 10.3389/fimmu.2018.00248.
［31］	Maalouf NS, Hanna D. Linear IgA bullous dermatosis successfully treated with omalizumab: a case report［J］. JAAD Case Rep, 2019,5（11）:966⁃969. doi: 10.1016/j.jdcr.2019.08.019.
［32］	Yamada S, Makino T, Jinnin M, et al. Association of linear IgA bullous disease with ulcerative colitis: a case of successful treatment with infliximab［J］. Dermatology, 2013,227（4）:295⁃298. doi: 10.1159/000355354.
［33］	Legendre L, Maza A, Almalki A, et al. Botulinum toxin a: an effective treatment for linear immunoglobulin A bullous dermatosis located in the axillae［J］. Acta Derm Venereol, 2016,96（1）:122⁃123. doi: 10.2340/00015555⁃2178.

[1]	魏瑾臧东杰曾三武蒋靖伦文辉. Dowling-Degos病1家系KRT5基因新突变分析[J]. 中华皮肤科杂志, 2022, 55(8): 703-705.
[2]	樊碧娆陈喜雪王明悦. [开放获取] 米诺环素单药或联合小剂量糖皮质激素治疗红斑型天疱疮15例和疱疹样天疱疮9例疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2022, 55(8): 676-681.
[3]	曹淼崇杉胡新媛朱学骏王明悦. 副肿瘤性天疱疮患者原发肿瘤切除后皮肤黏膜感染及管理分析[J]. 中华皮肤科杂志, 2022, 55(8): 669-675.
[4]	晋亮刘玲. 部分遗传性皮肤病的治疗进展[J]. 中华皮肤科杂志, 2022, 55(8): 735-739.
[5]	徐哲. 对遗传性皮肤病的一些思考[J]. 中华皮肤科杂志, 2022, 55(8): 651-652.
[6]	王媛李志量李锁荆可孙超梁桂熔张寒梅冯素英. 抗p200类天疱疮7例临床及免疫血清学特征分析[J]. 中华皮肤科杂志, 2022, 55(7): 557-561.
[7]	高子蕊赵培窦沅青刘萍张建中. 度普利尤单抗治疗成人结节性痒疹的疗效与安全性观察[J]. 中华皮肤科杂志, 2022, 55(7): 562-565.
[8]	王玲艳潘靖苗钢常晓丹金秋子郭宁宁张佳钰. 对生物制剂治疗抵抗的银屑病患者皮损部位分析[J]. 中华皮肤科杂志, 2022, 55(7): 583-587.
[9]	吕莎王爽武寒飞张明瑞胡馨李福秋. 孢子丝菌病研究进展[J]. 中华皮肤科杂志, 2022, 55(7): 629-632.
[10]	张宁李舒李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 55(7): 603-609.
[11]	中华医学会皮肤性病学分会特应性皮炎研究中心中华医学会皮肤性病学分会儿童学组. 【开放获取】度普利尤单抗治疗特应性皮炎专家共识[J]. 中华皮肤科杂志, 2022, 55(6): 465-470.
[12]	中国医师协会皮肤科医师分会自身免疫病专业委员会 . 【开放获取】环孢素治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2022, 55(6): 471-479.
[13]	赵柳琦陈妍陈丹阳樊碧娆王瑞尚盼盼陈喜雪朱学骏王明悦. 【开放获取】度普利尤单抗治疗大疱性类天疱疮21例的疗效及安全性回顾分析[J]. 中华皮肤科杂志, 2022, 55(6): 480-485.
[14]	黄馨陈筱昀李亚萍梁兴堃张桂英周英湛意罗帅寒天廖洁月肖嵘龙海. 度普利尤单抗治疗123例特应性皮炎的疗效及安全性分析[J]. 中华皮肤科杂志, 2022, 55(6): 486-493.
[15]	温广东冒丹丹张原媛窦沅青赵培吴晨雨张建中. 【开放获取】度普利尤单抗治疗泛发性苔藓状淀粉样变1例国内首报[J]. 中华皮肤科杂志, 2022, 55(6): 508-510.

线状IgA大疱性皮病的研究进展

Linear IgA bullous dermatosis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 33

相关文章 15

Metrics

本文评价

推荐阅读 10